Abstract

Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration

Author(s): Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J

Issue: Jan/Feb 2015 - Volume 19, Number 1

Page(s): 70-72

Download in electronic PDF format for $75
  • Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Page 1
  • Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Page 2
  • Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Page 3

Abstract

Intravitreal bevacizumab is frequently used off-label for the treatment of neovascular age-related macular degeneration, but there are concerns about the safety of intravitreal administered bevacizumab. It is suggested that repackaging bevacizumab in plastic syringes could affect the safety due to the unknown shelf life of the syringes. In this study, we analyzed the shelf life of the repackaged bevacizumab syringes, stored at 4°C, at certain time intervals. Over the 32 days tested, bevacizumab concentration and the pH were stable. However, the number of particles in the repackaged bevacizumab syringes increased during storage at 4°C and had exceeded the limits for intravitreal injections after 7 days. Since the number of particles seems to be the limitation of the shelf life of repackaged bevacizumab, it is necessary to quantify the number of particles in repackaged bevacizumab. Based on our results the maximum shelf life of repackaged bevacizumab should be 3 days.

Related Keywords

  • peer reviewed
  • bevacizumab
  • monoclonal antibody
  • intravitreal administration
  • neovascular age-related macular degeneration
  • eye diseases
  • ophthalmic disorders
  • plastic syringes
  • repackaging
  • shelf life
  • vascular endothelial growth factor antagonist
  • VEGF inhibitor
  • stability
  • particles
  • particulate contamination

Related Categories

  • OPHTHALMICS
  • PACKAGING
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2015
Pg. 70-72
Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration
Author(s): Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J
Jan/Feb 2008
Pg. 8-14
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
Author(s): Dib Jean G, Abdulmohsin Saud
May/Jun 2003
Pg. 170-174
Five Compounds for Treating Diabetes-Related Conditions
Author(s): Meece Jerry
Jul/Aug 2022
Pg. 330-335
Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes
Author(s): Bartoll Aaron Puplà, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
Jul/Aug 2011
Pg. 302-307
Treating Inner Ear Disorders with Intratympanic Drug Administration
Author(s): McElhiney Linda F
Jan/Feb 2017
Pg. 62
Infliximab 1% Ophthalmic Solution
Author(s): Allen Loyd V Jr
May/Jun 2012
Pg. 190-195
I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease
Author(s): McElhiney Linda F
Sep/Oct 2014
Pg. 418-426
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation
Author(s): Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Nov/Dec 2022
Pg. 446-466
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Sep/Oct 2008
Pg. 463-466
Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration
Author(s): Shields David E, Aclan Jennifer, Szatkowski Aaron
May/Jun 2003
Pg. 188-191
Treating Canine Hepatic Disease
Author(s): Davidson Gigi S
Nov/Dec 2016
Pg. 495-500
Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Author(s): Allen Loyd V Jr
Nov/Dec 2009
Pg. 506-515
Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Author(s): Mixon William, Angelle Patricea (Patsy), Chang Richard I
Jul/Aug 2022
Pg. 336-341
Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Author(s): Sahyoun Jean-Yves, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Sep/Oct 2016
Pg. 399-404
Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Author(s): Allen Loyd V Jr
Sep/Oct 2019
Pg. 414-417
Stability of Furosemide 5 mg/mL in Polypropylene Syringes
Author(s): van der Schaar JAJ, Grouls R, Franssen EJF, Crul M
Jan/Feb 2013
Pg. 28-38
Treatment Options for Male Hypogonadism
Author(s): Biundo Bruce
Jul/Aug 2013
Pg. 270-280
Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents
Author(s): Logomasini Mark A, Stout Richard R, Ron Marcinkoski
Jan/Feb 2024
Pg. 6-14
Treatment Options for Male Hypogonadism
Author(s): Biundo Bruce